SEC Form 4 · accession 0001645627-18-000015
ENDONOVO THERAPEUTICS, INC. · ENDV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Scott Mann
Officer — President · 10% Owner
Period of report
Mar 12, 2018
Accepted (ET)
Mar 19, 2018 · 8:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001528172
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 12, 2018 | P | 1,000 | $0.0396 | A | 24,862,189 | D | |
| Common Stock | Mar 12, 2018 | P | 1,000 | $0.04 | A | 24,863,189 | D | |
| Common Stock | Mar 13, 2018 | P | 1,000 | $0.0398 | A | 24,864,189 | D | |
| Common Stock | Mar 13, 2018 | P | 1,000 | $0.0374 | A | 24,865,189 | D | |
| Common Stock | Mar 13, 2018 | P | 1,000 | $0.038 | A | 24,866,189 | D | |
| Common Stock | Mar 13, 2018 | P | 1,000 | $0.039 | A | 24,867,189 | D | |
| Common Stock | Mar 13, 2018 | P | 1,000 | $0.0389 | A | 24,868,189 | D | |
| Common Stock | Mar 13, 2018 | P | 1,000 | $0.039 | A | 24,869,189 | D | |
| Common Stock | Mar 13, 2018 | P | 1,000 | $0.039 | A | 24,870,189 | D | |
| Common Stock | Mar 14, 2018 | P | 1,000 | $0.0389 | A | 24,871,189 | D | |
| Common Stock | Mar 14, 2018 | P | 1,000 | $0.0388 | A | 24,872,189 | D | |
| Common Stock | Mar 15, 2018 | P | 1,000 | $0.0375 | A | 24,873,189 | D | |
| Common Stock | Mar 15, 2018 | P | 1,000 | $0.0373 | A | 24,874,189 | D | |
| Common Stock | Mar 15, 2018 | P | 500 | $0.0374 | A | 24,874,689 | D | |
| Common Stock | Mar 16, 2018 | P | 1,000 | $0.0374 | A | 24,875,689 | D | |
| Common Stock | Mar 16, 2018 | P | 1,000 | $0.0369 | A | 24,876,689 | D | |
| Common Stock | Mar 16, 2018 | P | 1,000 | $0.0359 | A | 24,877,689 | D | |
| Common Stock | Mar 16, 2018 | P | 1,000 | $0.0367 | A | 24,878,689 | D | |
| Common Stock | Mar 16, 2018 | P | 1,000 | $0.0363 | A | 24,879,689 | D | |
| Common Stock | Mar 16, 2018 | P | 1,000 | $0.0369 | A | 24,880,689 | D |
Table II — derivative securities
No Table II lines on this filing.